This site is intended for healthcare professionals

New data from Phase III monarchE trial for Verzenio in high risk early breast cancer and Phase Ia data for LY 3484356.- Eli Lilly

Read time: 6 mins
Last updated:28th Jun 2021
Published:6th Jun 2021
Eli Lilly and Company announced new data for the investigational use of Verzenio (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO) .
Condition: Breast Cancer ER+ HER2 -
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest